Loading
Loading
Growth Hormone & Secretagogues · 10mg
Janoshik-tested · 10 vials per kit
CJC-1295 with DAC is a long-acting GHRH analog studied in preclinical and clinical research for its growth hormone-releasing properties. Its Drug Affinity Complex (DAC) technology enables a single dose to stimulate growth hormone secretion for several days, reducing dosing frequency. Research has explored applications in growth hormone deficiency, aging-related GH decline, and improvements in bone density, muscle strength, and skin elasticity.
≥98%
Purity
Lyophilised
Format
2–3 wks
Arrival
Don't want to wait 3 weeks?
Check local stock — weekday same/next-day delivery available.
Need to work out your dose?
Use our reconstitution calculator — syringe units in seconds.
Research Use Only — Disclaimer
This product is intended solely as a research chemical for laboratory and scientific study purposes only. It is not approved by the TGA or any regulatory body for human or animal consumption, therapeutic use, or clinical application. The information provided on this website is for educational purposes only. Handling must be limited to suitably qualified professionals operating within applicable laws and regulations. This product is not classified as a drug, food, cosmetic, or medicinal product and must not be used or labelled as such. By purchasing, you confirm you are a qualified research professional and accept full responsibility for compliance with all relevant laws in your jurisdiction.
CJC-1295 No DAC
Modified GRF(1-29)
CJC-1295 without DAC (also known as Modified GRF 1-29 or Mod GRF 1-29) is a 29-amino-acid analog of GHRH(1-44) stabilised by four amino acid substitutions (positions 2, 8, 15, and 27) but without the albumin-binding Drug Affinity Complex. This gives a half-life of ~30 minutes — substantially longer than endogenous GHRH (minutes) but far shorter than CJC-1295 DAC (days), producing discrete GH pulses rather than sustained GH elevation.
Acts on GHRH receptors (GHRHr) on anterior pituitary somatotrophs to stimulate GH synthesis and release, then clears quickly — mimicking a single physiological GHRH pulse. This pulsatile pattern is considered more biomimetic than sustained GH elevation from DAC forms. It is typically administered in combination with a ghrelin mimetic (Ipamorelin, GHRP-2) — the two receptor pathways (cAMP/PKA via GHRHr + IP3/PKC via GHS-R1a) are complementary, producing synergistic GH pulses 2-5× larger than either alone.
Modified GRF 1-29 is the most commonly studied short-acting GHRH analog in combination GH secretagogue protocols. Research encompasses GH-axis stimulation, body composition, recovery, sleep-associated GH release, and age-related GH decline. Its pulsatile GH release profile may better preserve hypothalamic-pituitary feedback compared to sustained-release forms.
For research reference only. All information pertains to preclinical or published human trial data. Not intended as medical advice. This product is for research use only.
Don't have supplies? Grab them while you're here.
